Sibylle Loibl

Sibylle Loibl contributed to the KATHERINE trial demonstrating T-DM1 benefit in HER2-positive patients with residual disease after neoadjuvant therapy and has led GBG neoadjuvant immunotherapy trials in TNBC. Her research focuses on escalation and de-escalation strategies based on neoadjuvant response, predictive biomarkers for IO in TNBC, and novel treatment combinations in early breast cancer. She is internationally recognized for translational work integrating genomic tumor features with treatment response in neoadjuvant breast cancer. Loibl contributes to ESMO, AGO, and ASCO guidelines for early breast cancer.